Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Fabrizio VernieriClaudia AltamuraNicoletta BrunelliCarmelina Maria CostaCinzia AuriliaGabriella EgeoLuisa FofiValentina FavoniCarlo LovatiDavide BertuzzoFlorindo d'OnofrioAlberto DorettiPaola Di FioreCinzia FinocchiFrancesca Schiano Di ColaAngelo RanieriBruno ColomboFrancesco BonoMaria AlbaneseSabina CevoliBarbanti Pieronull nullPublished in: European journal of neurology (2021)
Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients.